ACE2 and Diabetes: ACE of ACEs? by Batlle, Daniel et al.
ACE2 and Diabetes: ACE of ACEs?
Daniel Batlle,
1 Maria Jose Soler,
2 and Minghao Ye
1
T
he mechanisms involved in the development of
diabetes and its complications are complex, with
a long list of potential derangements on different
pathways (1,2). In this commentary, we discuss
angiotensin converting enzyme 2 (ACE2) as a potential
participant in the development of both islet -cell insufﬁ-
ciency early on and in the development of nephropathy later.
ACE has long been recognized as the key enzyme within
the renin-angiotensin system (RAS) mainly by cleaving
angiotensin (Ang) I to form Ang II, which is the main active
peptide within the system. ACE2, a homologue of ACE, is
a monocarboxypeptidase that preferentially removes car-
boxy-terminal amino acids from various substrates, in-
cluding Ang II, Ang I, and apelin (3–6). ACE2 cleaves Ang
II to form Ang-(1-7) with a high catalytic efﬁciency, sug-
gesting an important role in preventing Ang II accumula-
tion, while enhancing Ang-(1-7) formation (7) (Fig. 1).
Other mammalian homologues of ACE, such as collectrin
and, more recently, ACE3, have also been described (8).
ACE2, however, is the only known homologue of ACE with
enzymatic activity (3–5).
In the kidney, ACE2 colocalizes with ACE on the apical
surface area of the proximal tubules and is also localized
in the glomerulus (9). In the pancreas, ACE2 was found to
be localized to acini and islets following a similar distri-
bution to that of ACE (10). In rodent models of diabetes,
pharmacological inhibition of ACE2 (9,11) and genetic
ablation (12) have both been shown to worsen albumin-
uria and the associated glomerular lesions. Moreover,
decreased glomerular expression of ACE2 has been de-
scribed in rodent models of diabetes (9) and in human
kidney biopsies from patients with diabetic nephropathy
(13). Accordingly, ACE2 has been proposed as a target for
therapies aimed at increasing the activity of this enzyme as
a way to treat diabetic kidney disease (9,14) (Fig. 1).
In ACE2 deﬁcient mice, alterations in glucose tolerance
and reduced ﬁrst-phase insulin secretion have been de-
scribed, suggesting a potential role of ACE2 in the devel-
opment of diabetes (15). Collectrin, another homologue of
ACE, has also been shown to be expressed in -cells of the
pancreas, and although its function is unknown, it could
also be implicated in insulin secretion and -cell prolifer-
ation (16). Much like in the kidney, the pancreas expresses
key components of a local angiotensin peptide generating
system as described by Chappell et al. (17) almost 2
decades ago. These authors found Ang II to be the
predominant angiotensin peptide in the pancreas, with
lower levels of Ang-(1-7) and low to nondetectable levels
of Ang I. The effects of Ang II in the pancreas could be
counterbalanced by Ang-(1-7), as it has been proposed to
do in the kidneys and other tissues (18). The levels of both
peptides in the pancreas were several-fold higher than
those observed in the plasma (17). Carlsson et al. (19) later
found that Ang II can delay insulin secretion and reduces
blood ﬂow in the islets of Langerhans in a dose-dependent
manner. Consistent with this effect of Ang II, blockade of
RAS with either ACE inhibitors or Ang II receptor antag-
onists increases islet blood ﬂow (19). Moreover, these
agents have been shown to attenuate pancreatic inﬂam-
mation and ﬁbrosis (20). Also of note is the ﬁnding of
Tikellis et al. (10) that RAS blockade in the Zucker diabetic
fatty (ZDF) rat not only reduced islet ﬁbrosis, but also
improved structural parameters in association with im-
provement in ﬁrst-phase insulin secretion. These ﬁndings
are particularly relevant given clinical evidence that RAS
blockade may be associated with reduced incidence of
new-onset type 2 diabetes (21). Although recent trials have
called these results into question (22), there are ongoing
studies speciﬁcally designed to demonstrate that blockade
of the RAS helps prevent the development of type 2
diabetes.
In the October issue of Diabetes, Bindom et al. (23)
report studies examining ACE2 gene therapy in the db/db
model of type 2 diabetes. ACE2 gene therapy targeting the
islet cells through the use of adenoviral vectors increased
pancreatic ACE2 expression and activity in both db/db and
db/m mice, with a peak occurring 7 days after infection.
Prior to gene therapy at 8 weeks of age, pancreatic ACE2
was increased in the db/db mice. This ﬁnding is consistent
with a previous report by Tikellis et al. (10) in the ZDF rat
model of type 2 diabetes in which ACE as well as AT1
receptor expression was increased. It is likely that the
increase in ACE2 was an adaptive effort to counter ACE
overactivity. ACE2 gene therapy in the db/db mice resulted
in improved fasting blood glucose levels and glucose
tolerance (23). An increase in ﬁrst-phase insulin secretion
and -cell proliferation, as well as a reduction in -cell
apoptosis when compared with db/db mice receiving con-
trol adenoviral infection were also observed (23).
Unlike at 8 weeks of age, at 16 weeks of age db/db mice
showed a decrease in pancreatic ACE2 mRNA expression.
Also of note, 16-week-old db/db mice had much more
severe diabetes than the younger group, as indicated by
higher levels of fasting glucose, and they beneﬁted much
less from ACE2 gene therapy, showing no improvement in
glucose tolerance, ﬁrst-phase insulin secretion, -cell pro-
liferation, or apoptosis (23). Possibly, by 16 weeks of age
it is too late to intervene with ACE2 therapies because
signiﬁcant -cell failure may not be readily reversible. It
will be of interest to study whether increasing ACE2
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of type 1 diabetes such as the NOD mice and therefore
help prevent or delay the onset of the disease.
How could ACE and its homologues be involved in the
development of diabetes? The most obvious possibility is
that ACE and ACE2, by regulating the levels of Ang II
and/or Ang-(1-7) in pancreatic islets, are involved in the
control of insulin secretion to the extent that blood ﬂow is
inﬂuenced by local levels of angiotensin peptides as noted
above. Other effects of these peptides relevant to insulin
secretion in islet cells are listed in the ﬁgure. Similar
actions of these peptides at the kidney level may deter-
mine the fate of the decline in glomerular ﬁltration rate at
later phases of diabetes. It should be noted that, unlike
insulin secretion, insulin sensitivity did not improve after
ACE2 gene therapy in the db/db model at either 8 or 16
weeks of age (23). This lack of effect is somewhat unex-
pected because ACE2 overexpression should increase
Ang-(1-7) levels, as recently shown after recombinant
ACE2 protein administration (7). Ang-(1-7) has been
shown to increase insulin sensitivity (24), and moreover,
mice with genetic ablation of the Mas receptor, on which
Ang-(1-7) acts, develop features of metabolic syndrome,
including hyperinsulinemia and impaired glucose toler-
ance (25). The ﬁnding that -cell function improvement by
ACE2 overexpression was attenuated when a Mas-recep-
tor blocker was given, suggests, at least in part, mediation
by Ang-(1-7) (23).
In summary, ACE2 may play a pivotal role in diabetes: in
the pancreas, a relative deﬁciency of ACE2 as the disease
progresses may contribute to decreased insulin secretion,
whereas in the kidney glomerulus it may foster protein-
uria, as a result of both impaired degradation of Ang II and
the attendant Ang II accumulation locally. The ﬁndings of
Bindom et al. (23) that ACE2 overexpression by means of
adenoviral gene delivery can improve pancreatic islet
-cell function in db/db mice are exciting and are in
keeping with an important role of ACE2 as a therapeutic
target for diabetic kidney disease and several other con-
ditions in which overactivity of Ang II is undesirable.
ACE2, by fostering the degradation of Ang II and the
formation of Ang-(1-7), may have beneﬁcial effects on both
the kidney and pancreas (Fig. 1). ACE2 truly seems to be
the “good” ACE, and therapies aimed at amplifying its
activity should be explored in the prevention and treat-
ment of diabetes and its complications.
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